Global Bacillus Coagulans Market 2021 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Bacillus Coagulans Market 2021 (Includes Business Impact of COVID-19)
Global Bacillus Coagulans Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2030 is a recent report generated by Trusted Business Insights. The global bacillus coagulans market report has been segmented on the basis of type, application, and region.
Request Covid - 19 Impact
The global Bacillus Coagulans market size was valued at USD$346.21 million in 2020 and is projected to reach USD $619.37 million by 2030, and is anticipated to expand at a CAGR of 6.87% over the forecast period from 2020 to 2030.


Global Bacillus Coagulans Market: Overview


Bacillus Coagulans is a type of beneficial bacteria called as probiotic, that is majorly utilized for its probiotic nature. It improves gut health and slows the onset of stomach and digestive disorders. Some applications of bacterium in products such as bakery, beverages, dairy, confectionery, animal feed and functional food. Bacillus Coagulans used for various treatments such as digestive problems, lactose intolerance diarrhea, constipation, cholesterol reduction, bacterial vaginosis, and immunity enhancement. It is compatible with vitamins, electrolytes, enzymes, proteins, and carbohydrates, that makes it a cost-effective probiotic and used across wide range of food products.


Global Bacillus Coagulans Market: Dynamics


Technological advancements in probiotics industry is a key factor expected to drive growth of the global market over the forecast period.

In addition, rising obese population across the globe and prevalence of non-communicable diseases are some other factors expected to further fuel growth of the target market over the forecast period.

Moreover, increasing health awareness among consumers and increasing demand for bacillus coagulans products in emerging economies are some other factors expected to propel growth of the target market over the forecast period.

However, stringent government regulations regarding the approval of probiotics is a key factor expected to restrain growth of the global market over the forecast period.


Increasing health concerns among individuals and rising demand for functional foods across the globe are expected to create lucrative opportunities for the players operating in the global market over the forecast period. In addition, increasing investments by manufacturers for research and development activities of new probiotics products and launch of related new products are expected to create opportunities for the target market.

Manufacturers operating in the target market increasing focus on development of innovative products and improve their product offering by strategic business activities such as mergers, acquisitions, etc. which will support growth of the global market over the forecast period.


Global Bacillus Coagulans Market: Segment Analysis


Among the product segments, the food type segment is expected to register significant growth in terms of revenue over the forecast period.

Among the application segments, the functional food segment is expected to register significant growth in terms of revenue and it is expected to continue its significance over the forecast period.


Global Bacillus Coagulans Market: Regional Analysis


The market in North America is expected to dominate in the global market in terms of revenue over the forecast period, owing to increasing hectic lifestyle of working people and changing their eating habits which in turn is expected to increase their focus towards nutritional food products across various countries in this region.

The market in Asia Pacific is expected to register significant growth over the forecast period, owing to increasing incidences of chronic disorders and growing obese population across various countries in this region.


Below are the active patents related to Bacillus Coagulans Market.


Patent Number: US8492127B2

Bacillus coagulans strains and their applications in L-lactic acid production

Abstract

The invention is concerned with the strains of B. coagulans for lactic acid production and the related methods, in which the carbon sources are pentose or hexose or the agricultural or industrial wastes containing pentose or hexose or a mixture of both. According to the invention, the highest amount of L-lactic acid produced from glucose is 173 g/L, the optical purity is over 99%, the yield is up to 0.98, and the productivity is up to 2.4 g/L per hour. The highest amount of L-lactic acid produced from xylose is 195 g/L, the optical purity is over 99%, the yield is up to 0.98, and the productivity is up to 2.7 g/L per hour. The highest amount of L-lactic acid produced from reducing sugars in xylitol byproducts is 106 g/L, the optical purity is over 99%, and the productivity is up to 2.08 g/L per hour. The B. coagulans strains XZL4 (DSM No. 23183) and XZL9 (DSM No. 23184) of the invention can directly utilize various reducing sugars in xylitol byproducts to produce high amounts of L-lactic acid, which improves the production efficiency at low costs, and the strains are, thus, appropriate for industrial productions.

Application File Date: 2010-11-22

Application Granted Date: 2013-07-23

Current Assignee: Shanghai Jiaotong University

Patent Number: US20160074495A1

Inactivated Bacterial Cell Formulation

Abstract

The invention relates to the use of lactic acid-producing bacteria to boost the immune system.

Application File Date: 2015-11-23

Application Granted Date: 2016-09-20

Current Assignee: Ganeden Biotech Inc

Global Bacillus Coagulans Market Segmentation:

Segmentation by product:

  
Food Type
  
Pharmaceutical Type

Segmentation by application:

  
Bakery Products
  
Confectionery
  
Dairy Products
  
Beverages
  
Functional Food
  
Animal Feed


Key Market Players included in the report:


  
Aumgene Biosciences
  
Ganeden, Inc.
  
Microbax (india) Limited
  
Mitsubishi
  
MYSTICAL BIOTECH
  
Nebraska Cultures Inc.
  
Sabinsa Corporation
  
Sanzyme Ltd.
  
Synbiotech
  
Syngen Biotech Co., Ltd.
  
UAS Laboratories, Inc.
  
Unique Biotech Ltd.


Below are the key development related to Bacillus Coagulans Market in 2020 and 2021.


JULY 2020: Sabinsa Earns Non-GMO Project Verification for Eleven Key Ingredients. The Non-GMO Project Verified is North America’s leading independent third-party verification for products that are produced according to best practices in avoiding Genetically Modified Organisms (GMO). Products bearing the Non-GMO Project Verified seal have gone through a comprehensive evaluation process according to a consensus-based rigorous standard, which includes traceability, segregation, and meaningful, ongoing testing of high GMO risk ingredients. Sabinsas key ingredients earning Non-GMO Project Verified certification include. Boswellin® Super Boswellia (Boswellia serrata) Extract Curcumin C3 Complex® Turmeric (Curcuma longa) Extract  Shagandha® Root Extract 2.5 % USP (Withania somnifera) Livinol™ Kokum (Garcinia indica) Extract Saberry® Amla (Emblica officinalis) Extract Cococin™ Coconut (Cocos nucifera) Water Solids BioPerine® Black Pepper (Piper nigrum) Extract LactoSpore® Bacillus coagulans MTCC 5856 Probiotic in three grades: 6B, 15B, and 100B. Source

January 2020: Fermented Sciences Inc. Announces Worlds First Shelf-Stable Probiotic Technology Makers of Flying Embers Hard Kombucha pioneering new advances in the world of better-for-you alcoholic beverages in partnership with zümXR®. Fermented Sciences, Inc. (FSI) maker of Flying Embers Hard Kombucha has developed a proprietary process in partnership with zümXR®, utilizing a patented technology to create the worlds first shelf stable probiotic hard kombucha. Flying Embers contains both live probiotics and native kombucha bacteria without the use of pasteurization. Fermented Sciences Inc. (FSI) was founded in 2017 by Bill Moses, a well-known expert in the art and science of fermentation, co-founder and former CEO of KeVita, which he sold to PepsiCo. Flying Embers handcrafted hard kombucha is the first product line developed and launched by FSI. The patented probiotic encapsulation technology, developed in an exclusive partnership with zümXR®, ensures that the probiotic strain of Bacillus coagulans SNZ 1969 and the kombucha bacteria can continue to thrive at room temperatures without dying off. Source